Celerion is pleased to announce the appointment of Clayton Dehn as Executive Director, Metabolic Diseases. Mr. Dehn will lead the expansion of Celerion’s current capabilities that support early Proof-of-Concept in the development of diabetes, obesity, metabolic and cardio-metabolic interventions.
The appointment of Mr. Dehn reinforces Celerion’s commitment to accelerating drug development through Applied Translational Medicine. Clients working in the metabolic area will have access to an arsenal of complex, highly sensitive pharmacodynamic tests capable of detecting early signals of efficacy.
Help employers find you! Check out all the jobs and post your resume.
